PF 219061 is an selective agonist for dopamine 3 receptor with an EC50 of 15 nM. PF 219061 exhibits a rapid absorption and a good liver blood clearance, and can be used for research of female sexual dysfunction.

PD 118717 is a selective dopamine (DA) D-2 autoreceptor agonist. PD 118717 has significant affinity for 5-HT1A but not 5-HT1B and 5-HT2 receptors. PD 118717 is active in antagonizing the tau-Butyrolactone-induced accumulation of dopa in rat striatum and mesolimbic regions. PD 118717 exhibits an antipsychotic-like profile.

Nolomirole (CHF 1035) is an orally active and selective DA2 dopaminergic receptor/α2-adrenoceptor agonist. Nolomirole attenuates the heart failure signs in the Monocrotaline-induced congestive heart failure model. Nolomirole increases cardiac output.

N-Methylspiroperidol is a D2 receptor antagonist. N-Methylspiroperidol can be labeled as [18F]N-Methylspiroperidol and used in PET (Positron Emission Tomography) to study how it binds to the 5-HT2C receptor and the competition and effects of neurotransmitters like dopamine on these receptors.

Nitracaine is a structural analog of Dimethocaine in the colon, offering various anti-inflammatory effects in areas of colitis, and it also exerts related anticancer effects by regulating the IL-6/STAT3 pathway.

Clozapine (HF 1854) dihydrochloride is an antipsychotic used for the research of schizophrenia. Clozapine has high affinity for a number of neuroreceptors. Clozapine is a potent antagonist of dopamine D2 with a Ki of 75 nM. Clozapine inhibits the muscarinic M1 receptor and serotonin 5HT2A receptor with Kis of 9.5 nM and 4 nM, respectively. Clozapine is also a potent and selective agonist at the muscarinic M4 receptor (EC50=11 nM).

Aripiprazole N-oxide is a metabolite of the atypical antipsychotic Aripiprazole. Lenvatinib (E708

7-Hydroxy ropinirole (SK&F 89124) bromide is a potent and highly selective DA2 receptor agonist, and a derivative of N,N-di-n-propyldopamine (DPDA). In isolated perfused rabbit ear artery models, 7-Hydroxy ropinirole (bromide) exerts its DA2 agonist effects by inhibiting neurotransmitter release or sympathetic nerve-induced responses. It shows potential for research in the fields of cardiovascular and neurological diseases.

2-Bromo-LSD (BOL-148; Bromolysergide) is a Dopamine Receptor antagonist that directly affects dopamine neurons in the substantia nigra neostriatum. 2-Bromo-LSD increases the hydroxylation of tyrosine in striatum and antagonizes the decrease of Apomorphine-induced DOPA accumulation. 2-Bromo-LSD also blocks the 5-HT Receptor mediated DOPA formation.

Sut-8701 is a Cholecystokinin analog that effectively slows the degenerative process of Alzheimer's disease by protecting the integrity of cholinergic neurons in the nucleus basalis.

CI-1015 is a potent CCK-B receptor antagonist.

A-70874 is a tyrosine-free tetrapeptide analog of cholecystokinin (30-33) (CCK-4). A-70874 is an agonist that stimulates pancreatic amylase release and a partial agonist that stimulates pancreatic phosphoinositide decomposition. A-70874 has an IC50 of 4.9 nM for the guinea pig pancreatic CCK receptor. Cholecystokinin (CCK) receptors are divided into CCK-A (digestive tract) and CCK-B (brain). A-70874 has an affinity of 1.6 μM for the CCK-B/gastrin receptor.

Rimegepant (sulfate hydrate) is an orally active, selective and competitive calcitonin gene-related peptide (CGRP) receptor antagonist with a Ki of 0.027 nM. Rimegepant (sulfate hydrate) can be used in migraine related research.

Δ9-THCP acetate (Δ9-Tetrahydrocannabiphorol acetate) is structurally similar to known phytocannabinoids.

Δ9-THCBA-A (Δ9-Tetrahydrocannabinolic acid-C4) is structurally similar to known phytocannabinoids.

Δ9-Tetrahydrocannabiorcol is structurally similar to known phytocannabinoids.

Δ8-THCPA-A (Δ8-Tetrahydrocannabiphorolic acid) is structurally similar to known phytocannabinoids.

Δ8-THCP (Δ8-Tetrahydrocannabiphorol; n-Heptyl Δ8-THC) (Compound 1a) is a semisynthetic cannabinoid that serves as an analytical reference standard and exhibits affinity for the CB1 receptor.

Δ8-THC-ethyl (Ethyl-Δ8-Tetrahydrocannabinol) is structurally similar to known phytocannabinoids.

Δ8-THCBA-A (Δ8-Tetrahydrocannabibutolic acid A) is structurally similar to known phytocannabinoids.

Δ8-THCB (∆8-Tetrahydrocannabutol) is a structural analog of phytocannabinoids. Δ8-THCB is also an analog of Δ8-tetrahydrocannabinol.

Δ8-THC methyl ether (compound 3) shows a good docking score (-10.167 kcal/mol) for CB2 receptor. Δ8-THC methyl ether has antinociceptive activity in mice.

Δ8-THC Glucuronide is a phytocannabinoid metabolite.

Δ8-Tetrahydrocannabivarin is a cannabinoid.

Δ8-iso-THC is structurally similar to known phytocannabinoids.

Δ4-Iso-THC (Δ4-Iso-tetrahydrocannabinol) is a cannabidiol derivative with potential cytotoxicity targeting cancer cells.

Δ4(8)-iso-THC (Δ4(8)-Isotetrahydrocannabinol) is structurally similar to known phytocannabinoids.

Surinabant (SR 147778) is an orally active, selective cannabinoid receptor type 1 CB1R antagonist. Surinabant is used in studies of obesity and alcoholism.

Rezosicone is the antagonist for cannabinoid CB1 receptor.

PTI-1 is a synthetic cannabinoid (CB) that contains the 1-pentyl-indole structure.